IP Library › Granted Patent US 12,186,335
Granted Patent B2
US 12,186,335 · App. 16/856,861 · Granted Jan 7, 2025

Methods and compositions for inhibiting enveloped viruses using high molecular weight hydrophobically modified alkali swellable emulsion polymers and surfactant

Inventors: Elizabeth Bruning (Skillman, NJ); Anthony Robert Geonnotti, III (Skillman, NJ); Euen Thomas Ekman-Gunn (Skillman, NJ); Russel Walters (Skillman, NJ); Alpana Oak (Skillman, NJ); Frank C. Sun (Skillman, NJ); Kimberly Capone (Skillman, NJ); Frank J. Kirchner (Skillman, NJ)
Assignee: Johnson & Johnson Consumer Inc.
A61K31/78A61K9/0014A61K31/085A61P31/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,186,335
App. No.
16/856,861
Granted
Jan 7, 2025
Kind
B2
Abstract

This invention relates to methods and compositions for inhibiting the transmission of enveloped viruses, which entails applying a composition containing a high molecular weight hydrophobically-modified polymer to an infectable or ingestible surface that may contain viruses and wherein said anti-viral composition comprises less than about 9% by weight of surfactant having an HLB greater than about 12.

Claims (18)

1. A method of inhibiting entry of enveloped viruses into cells comprising contacting said viruses with an anti-viral composition comprising at least one hydrophobically modified polymer having a number average molecular weight (M n ) of more than 100,000 as measured by gel permeation chromatography (GPC) calibrated with a poly(methyl methacrylate) (PMMA) standard,

wherein the hydrophobically modified polymer is a hydrophobically modified alkali swellable emulsion polymer, which is polyacrylate-33,

wherein the amount of said hydrophobically modified polymer is from about 0.00005% to about 3% by weight of the anti-viral composition,

wherein the anti-viral composition comprises less than about 9% by weight of surfactant having an HLB greater than about 12,

wherein said contacting is done by applying the anti-viral composition to skin or mucosal tissue of a subject,

wherein the formulated anti-viral composition, upon application that contacts the enveloped viruses, inhibits entry of the enveloped viruses into cells, and

wherein the enveloped virus is human immunodeficiency virus type 1 (HIV-1).

2. The method of claim 1 , wherein the anti-viral composition comprises from about 0.375% to less than about 9% by weight of surfactant.

3. The method of claim 2 , wherein the anti-viral composition comprises between about 0.375% and 6% by weight of surfactant.

4. The method of claim 2 , wherein the anti-viral composition comprises between about 0.375% and 3% by weight of surfactant.

5. The method of claim 1 , wherein the trans-epithelial permeability (TEP) of the anti-viral composition is greater than about 3.7.

6. The method of claim 1 , wherein the mucosal tissue comprises tissue selected from the group consisting of oral tissue, ocular tissue, nasal tissue, vaginal tissue, rectal tissue and a combination thereof.

7. The method of claim 1 , wherein the anti-viral composition further comprises at least 55% of water.

8. The method of claim 7 , wherein the anti-viral composition comprises at least 97% of water.

9. The method of claim 1 , wherein the inhibition of virus entry into said cells results in the reduction of potential for viral infection.

10. The method of claim 1 , wherein the anti-viral composition does not substantially disrupt biological surfaces.

11. The method of claim 1 , wherein the anti-viral composition comprises a dosage form selected from the group consisting of: a liquid, a lotion, a cream, a gel, a stick, a spray, a shaving cream, an ointment, a cleansing liquid wash, a solid bar, a shampoo, a paste, a powder, a mousse, a wipe, a patch, a wound dressing, an adhesive bandage, a hydrogel and a film.

12. The method of claim 1 , wherein the anti-viral composition further comprises nonoxynol-9.

Assignments (7)
CHANGE OF NAME Recorded Oct 28, 2024
From: JOHNSON & JOHNSON CONSUMER INC.
To: KENVUE BRANDS LLC
Reel/Frame 069267/0143 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2023
From: JOHNSON & JOHNSON CONSUMER INC.
To: JOHNSON & JOHNSON CONSUMER INC.
Reel/Frame 062438/0372 →
CERTIFICATE OF CONVERSION Recorded Jan 19, 2023
From: JOHNSON & JOHNSON CONSUMER INC.
To: JOHNSON & JOHNSON CONSUMER INC.
Reel/Frame 062438/0521 →
MERGER Recorded Jan 27, 2022
From: JOHNSON & JOHNSON CONSUMER INC.
To: CHENANGO ZERO LLC
Reel/Frame 059618/0521 →
MERGER AND CHANGE OF NAME Recorded Jan 27, 2022
From: CHENANGO TWO LLC; CURRAHEE HOLDING COMPANY INC.
To: JOHNSON & JOHNSON CONSUMER INC.
Reel/Frame 058888/0210 →
MERGER Recorded Jan 27, 2022
From: CHENANGO ZERO LLC
To: CHENANGO TWO LLC
Reel/Frame 058888/0133 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2021
From: BRUNING, ELIZABETH; GEONNOTTI, ANTHONY ROBERT; EKMAN-GUNN, EUEN THOMAS; WALTERS, RUSSEL; SUN, FRANK C.; CAPONE, KIMBERLY; KIRCHNER, FRANK J.
To: JOHNSON & JOHNSON CONSUMER INC.
Reel/Frame 054959/0645 →
Continuity (1)
Related Publication 20210330701A1 · Oct 28, 2021
References Cited (57)
US 3755560A · Dickert et al. · 1973 [cited by applicant]
US 4384096A · Sonnabend · 1983 [cited by applicant]
US 4421769A · Dixon et al. · 1983 [cited by applicant]
US 5874495A · Robinson · 1999 [cited by applicant]
US 7157414B2 · Librizzi et al. · 2007 [cited by applicant]
US 7772421B2 · Yang et al. · 2010 [cited by applicant]
US 7803403B2 · Librizzi et al. · 2010 [cited by applicant]
US 7892525B2 · Faivre et al. · 2011 [cited by applicant]
US 8025902B2 · Librizzi et al. · 2011 [cited by applicant]
US 8211850B2 · Andjelic et al. · 2012 [cited by applicant]
US 8293845B2 · Tamareselvy et al. · 2012 [cited by applicant]
US 8329626B2 · Gunn et al. · 2012 [cited by applicant]
US 8329627B2 · Gunn et al. · 2012 [cited by applicant]
US 8343902B2 · Walters et al. · 2013 [cited by applicant]
US 8623935B2 · Hobbs et al. · 2014 [cited by applicant]
US 9068148B2 · Tamareselvy et al. · 2015 [cited by applicant]
US 9931290B2 · Tamareselvy et al. · 2018 [cited by applicant]
US 10435308B2 · Man et al. · 2019 [cited by applicant]
US 10517806B2 · Emiru et al. · 2019 [cited by applicant]
US 20020051797A1 · Jezior · 2002 [cited by applicant]
US 20040224005A1 · Gabbay · 2004 [cited by applicant]
US 20050069566A1 · Tamarkin et al. · 2005 [cited by applicant]
US 20050244365A1 · Labib · 2005 [cited by examiner]
US 20080139656A1 · Taylor et al. · 2008 [cited by applicant]
US 20090185995A1 · Vochecowicz et al. · 2009 [cited by applicant]
US 20100008938A1 · Diwan et al. · 2010 [cited by applicant]
US 20140234249A1 · Capone · 2014 [cited by examiner]
US 20160262999A1 · Pedersen et al. · 2016 [cited by applicant]
EP 226097B1 · 1986 [cited by applicant]
EP 705852B1 · 1996 [cited by applicant]
GB 2346891A · 2000 [cited by applicant]
WO WO2005074947 · 2005 [cited by applicant]
WO WO2008014824A1 · 2008 [cited by applicant]
WO WO2008036587A2 · 2008 [cited by applicant]
WO WO2008036134 · 2008 [cited by applicant]
WO WO2014130432 · 2014 [cited by applicant]
Robertson et al. (Mar. 1995). “Recombination in AIDS viruses.” Journal of Molecular Evolution. 40 (3):249-59. [cited by applicant]
Liu et al., Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases, ACS Cent. Sci. 2020, 6, 315-331). [cited by applicant]
Blaising et al., Arbidol as a broad-spectrum antiviral: An update, Antiviral Research, 107 (2014) 84-94. [cited by applicant]
Kadam et al., Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol, PNAS Jan. 10, 2017 114 (2) 206-214. [cited by applicant]
Matsumura, et al.; “Amphipathic DNA Polymers Inhibit Hepatitis C Virus Infection by Blocking Viral Entry,” Gastroenterology, Elsevier Inc., vol. 137, No. 2, Aug. 1, 2009, pp. 673-681. [cited by applicant]
Fisher Kevin; “Final Report on the Safety Assessment of Nonoxynols -2, -4, -8, -9, -10, -12, -14, -15, -30, -40, and -50,” Journal of the American College of Toxicology Volume, vol. 2, No. 7; Jan. 1, 1983; pp. 35-60. [cited by applicant]
Int'l. Search Report; PCT/IB2021/053205; dated Jun. 30, 2021. [cited by applicant]
Menachery et al., Pathogenic Influenza Viruses and Coronaviruses Utilize Similar and Contrasting Approaches to Control Interferon-Stimulated Gene Responses, American Society of Microbiology, 2014, 5(3): 1-11. [cited by applicant]
Li, Structure, Function and Evolution of Coronavirus Spike Proteins, Annu. Rev. Virul. 2016, 3(1):237-261. [cited by applicant]
Sagarin, Cosmetics, Science and Technology, 2nd Edition, vol. 1, pp. 32-43 (1972) and the International Cosmetic Ingredient Dictionary and Handbook, eds. Wenninger and McEwen, pp. 1656-1661, 1626, and 1654-55 (The Cosme… [cited by applicant]
Sagarin, Cosmetics, Science and Technology, 2nd Edition, vol. 1, pp. 72-73 (1972) and the ICI Handbook pp. 1693-1697. [cited by applicant]
McCutcheon's Detergents and Emulsifiers, North American Edition, pp. 317-324 (1986), and the ICI Handbook, pp. 1673-1686. [cited by applicant]
Mintel Report Record ID No. 1867920; Neutrogena Ultra Gentle Daily Care Face Cleanser; Date Published Sep. 2012. [cited by applicant]
Mintel Report Record ID No. 5114245; Johnson's baby moisture wash; Date Published Sep. 2017. [cited by applicant]
Mintel Report Record ID No. 2165545; Johnson's baby Head-to-Toe washcloths; Published Sep. 2013. [cited by applicant]
NIH Report; Vaccine Company Develops Nasal Antiseptic That Kills Coronavirus in Lab Studies; https://projectreporter.nih.gov/Reporter_Viewsh.cfm?sl=14E8CD0F4B8AC3D17598B8961CAA4A01A2FFCEB861BF; dated Jun. 30, 2020. [cited by applicant]
Solvay: “Rheomer 33T datasheet”, Sep. 1, 2013 (Sep. 1, 2013), pp. 1-2, XP0931 5421 0, Retrieved from the Internet: U RL:https://glenncorp.com/wp-content/uploads/2014/04/ Rheomer-33T.PDS_. 09.01 .1 3.pdf. [cited by applicant]
Vardanyan R.S., Hruby V.J.; Antiviral Drugs; Chapter in Book “Synthesis of Essential Drugs”, Dated 2006, pp. 549-557, p. 549. [cited by applicant]
Sutyagin V.M. et al., “Chemistry and Physics of Polymers: Textbook” [in Russian], Tomsk: TPU Publishing House, 2003, 208 pages; (see p. 142 para. 1-2 from the bottom, p. 132 para. 4-5 from the bottom, p. 140 para. 2 fro… [cited by applicant]
Maskovskij M.D.; [Drugs], 16 [cited by applicant]
Kondrat'eva T.S., et al.; Technology of Medicinal Forms: Textbook in 2 volumes, vol. 1, Moscow: Medicine, dated 1991, 496 pages, pp. 36, 37, 74, 76. [cited by applicant]